THE LONGEST OS EVER

REPORTED IN ALK+ mNSCLC1
 

DEMONSTRATING 81 MONTHS OF MEDIAN OS  VS. CRIZOTINIB1

 


 

OVER 137,000 PATIENTS
TREATED WORLDWIDE15
 


 

Discover

ALECENSA


ALK, anaplastic lymphoma kinase; mNSCLC, metastatic non-small cell lung cancer; NSCLC, non-small cell lung cancer; OS, overall survival.

 

1. Peters S, et al. Ann Oncol 2025. DOI: 10.1016/j.annonc.2025.09.018. 2. Mok T, et al. Ann Oncol 2020;31:1056–1064. 3. Peters S, et al. N Engl J Med 2017;377:819–838. 4. Wu YL, et al. N Engl J Med 2024;390:1265–1276. 5. Dziadziuszko R, et al. J Thorac Oncol 2021;16:2040–2050. 6. Gadgeel SM, et al. Ann Oncol 2023;34:S782–S783. 7. Wolf J, et al. ESMO Open 2022;7:100333. 8. Nakagawa K, et al. Lung Cancer 2020;139:195–199. 9. Novello S, et al. Annals Oncol 2018;29:1409–1416. 10. Arrieta O, et al. Nat Commun 2025;16:4553. 11. Barlesi F, et al. Ann Oncol 2016;27(Supplement 6):vi416–vi545. 12. Yang JCH, et al. Thorac Oncol 2017;12:1552–1560. 13. Ou SH, et al. J Clin Oncol 2016;34:661–668. 14. Shaw AT, et al. Lancet Oncol 2016;17:234–242. 15. Roche. Data on File.

 

© 2025 F. Hoffmann-La Roche Ltd. M-XX-00021690; Date of preparation: December 2025 Legal Statement - Privacy Policy - Cookie Preferences